HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Adel Giaid Selected Research

SB-611812

5/2008Urotensin-II and cardiovascular remodeling.
11/2006Urotensin-II receptor blockade with SB-611812 attenuates cardiac remodeling in experimental ischemic heart disease.
8/2006Urotensin-II blockade with SB-611812 attenuates cardiac dysfunction in a rat model of coronary artery ligation.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Adel Giaid Research Topics

Disease

6Cardiovascular Diseases (Cardiovascular Disease)
09/2009 - 10/2004
5Atherosclerosis
09/2009 - 06/2003
5Heart Failure
11/2006 - 06/2002
4Fibrosis (Cirrhosis)
01/2010 - 11/2006
3Hypertrophy
05/2008 - 06/2003
3Coronary Artery Disease (Coronary Atherosclerosis)
05/2008 - 10/2004
2Hypertension (High Blood Pressure)
01/2011 - 10/2004
2Insulin Resistance
01/2011 - 10/2004
2Vascular Remodeling
12/2005 - 11/2005
2Myocardial Infarction
02/2003 - 07/2002
1Hyperlipoproteinemia Type II (Familial Hypercholesterolemia)
12/2011
1Fatty Liver
05/2011
1Inflammation (Inflammations)
01/2011
1Lymphangioleiomyomatosis (Lymphangiomyomatosis)
08/2010
1Neoplasms (Cancer)
08/2010
1Pulmonary Fibrosis (Fibrosing Alveolitis)
01/2010
1Hyperlipidemias (Hyperlipidemia)
09/2009
1Atherosclerotic Plaque (Atheroma)
06/2009
1Myocardial Ischemia (Ischemic Heart Diseases)
11/2006
1Edema (Dropsy)
08/2006
1Lung Injury
04/2006
1Hyperoxia
04/2006
1Acute Coronary Syndrome
03/2006
1Metabolic Syndrome (Dysmetabolic Syndrome X)
10/2004
1Abdominal Aortic Aneurysm
09/2004
1Rhinosinusitis
01/2004
1Pulmonary Hypertension
06/2003
1Infarction (Infarctions)
02/2003
1Renal Cell Carcinoma (Grawitz Tumor)
07/2002

Drug/Important Bio-Agent (IBA)

13urotensin IIIBA
08/2010 - 06/2002
6Peptides (Polypeptides)IBA
08/2010 - 10/2004
4Proteins (Proteins, Gene)FDA Link
08/2010 - 11/2006
3CholesterolIBA
12/2011 - 10/2004
3SB-611812IBA
05/2008 - 08/2006
3CollagenIBA
12/2006 - 11/2005
2Endothelin-1 (Endothelin 1)IBA
01/2010 - 06/2003
2Apolipoproteins E (ApoE)IBA
09/2009 - 06/2009
2Messenger RNA (mRNA)IBA
05/2008 - 09/2004
1LDL Receptors (LDL Receptor)IBA
12/2011
1LDL CholesterolIBA
05/2011
1Acyl Coenzyme A (Acyl CoA)IBA
01/2011
1lipoarabinomannan (LAM)IBA
08/2010
1Tuberous Sclerosis Complex 2 ProteinIBA
08/2010
1UrotensinsIBA
08/2010
1TOR Serine-Threonine KinasesIBA
08/2010
1Lipoproteins (Lipoprotein)IBA
09/2009
1LipidsIBA
09/2009
1C.I. direct red 80IBA
11/2006
1Collagen Type I (Type I Collagen)IBA
11/2006
1OzoneIBA
04/2006
1Heme Oxygenase-1IBA
04/2006
1Small Interfering RNA (siRNA)IBA
04/2006
1MitogensIBA
10/2004
1Tissue ExtractsIBA
09/2004
1prostaglandin R2 D-isomerase (prostaglandin D2 synthase)IBA
01/2004
1Prostaglandin D2IBA
01/2004
1Reactive Oxygen Species (Oxygen Radicals)IBA
06/2003
1Endothelins (Endothelin)IBA
06/2003
1EnzymesIBA
02/2003
1Cyclooxygenase 2 (Cyclooxygenase-2)IBA
02/2003
1Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)IBA
02/2003
1Nitric Oxide Synthase (NO Synthase)IBA
07/2002
1Nitric Oxide Synthase Type II (Inducible Nitric Oxide Synthase)IBA
07/2002

Therapy/Procedure

2Ligation
11/2006 - 02/2003
1Stents
03/2007
1Intranasal Administration
04/2006
1Glycemic Control
10/2004